{"id":186,"date":"2026-06-02T09:00:00","date_gmt":"2026-06-02T09:00:00","guid":{"rendered":"https:\/\/arenasignals.com\/?p=186"},"modified":"2026-10-08T01:41:34","modified_gmt":"2026-10-08T01:41:34","slug":"neuronetics-robert-greene-appointed-senior-vice-president-of-sales","status":"publish","type":"post","link":"https:\/\/arenasignals.com\/?p=186","title":{"rendered":"Neuronetics: Robert Greene appointed Senior Vice President of Sales"},"content":{"rendered":"
\n
Signal strength<\/strong> \u00b7 Commercial leadership<\/span>\u2605\u2605\u2605\u2606\u2606<\/span><\/div>\n
\n

Arena Signals interpretation<\/h2>\n

Neuronetics needs stronger NeuroStar utilization as well as new system placements. Greene\u2019s experience in capital equipment and service-based healthcare sales makes this an important execution hire for rebuilding the commercial engine.<\/p>\n<\/section>\n

\n

News summary<\/h2>\n

Robert Greene appointed Senior Vice President of Sales.<\/p>\n<\/section>\n

<\/p>\n

\n

Full company announcement<\/h2>\n
\n

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar\u00ae Advanced Therapy, today announced that Robert Greene has been appointed as the company\u2019s Senior Vice President Sales, effective June 1, 2026.<\/p>\n

Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service.<\/p>\n

Inducement\u00a0Grant\u00a0under Nasdaq Listing Rule 5635(c)(4)<\/strong><\/p>\n

In connection with his hiring on\u00a0June 1, 2026, the Compensation Committee of the Company\u2019s Board of Directors authorized the grant to\u00a0Mr. Greene\u00a0of restricted stock units representing 200,000 shares of the Company\u2019s common stock in accordance with Nasdaq Listing Rule 5635(c)(4), which will vest in four equal annual installments on the anniversary of the grant date, subject to\u00a0Mr. Greene\u2019s continued employment with the company and subject to Capitalization Adjustments (as defined in the Company\u2019s 2020 Inducement Incentive Plan).<\/p>\n

About\u00a0Neuronetics<\/strong><\/p>\n

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (\u201cGreenbrook\u201d) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (\u201cMDD\u201d) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (\u201cTMS\u201d) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world\u2019s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO\u00ae (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1<\/sup><\/p>\n

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com<\/a>.<\/p>\n

Investors:<\/strong><\/p>\n

Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com<\/p>\n

Media:
<\/strong>EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com<\/a><\/p>\n

References<\/strong>
1\u00a0<\/sup>The effectiveness of SPRAVATO\u00ae\u00a0in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO\u00ae\u00a0does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO\u00ae. For more important safety information about SPRAVATO\u00ae, please visit\u00a0spravatohcp.com<\/strong><\/a>.<\/p>\n

\n <\/div>\n

Source: Neuronetics via GlobeNewswire<\/a>. Announcement text supplied by the publisher; Arena Signals interpretation appears above.<\/p>\n<\/section>\n

<\/p>\n

Read the full Neuronetics Arena Signals report \u2192<\/a><\/p>\n

From the News Flow section of the Arena Signals report. Signal date and interpretation retained from that report.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Robert Greene appointed Senior Vice President of Sales.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"arena_status":[2],"arena_format":[5],"class_list":["post-186","post","type-post","status-publish","format-standard","hentry","category-health","arena_status-public","arena_format-news-signal","asns-article"],"_links":{"self":[{"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/posts\/186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=186"}],"version-history":[{"count":1,"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/posts\/186\/revisions"}],"predecessor-version":[{"id":261,"href":"https:\/\/arenasignals.com\/index.php?rest_route=\/wp\/v2\/posts\/186\/revisions\/261"}],"wp:attachment":[{"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=186"},{"taxonomy":"arena_status","embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Farena_status&post=186"},{"taxonomy":"arena_format","embeddable":true,"href":"https:\/\/arenasignals.com\/index.php?rest_route=%2Fwp%2Fv2%2Farena_format&post=186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}